undertakes

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Source Node:
Time Stamp: October 13, 2023 5:16 AM - Modified On: October 13, 2023 - Published By:
Source Cluster:
Republished By Plato

In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis in

Nutriband’s Innovative Patent Breaks New Ground in Transdermal Medications

Source Node:
Time Stamp: September 20, 2023 8:36 AM - Modified On: September 20, 2023 - Published By:
Source Cluster:
Republished By Plato

Revolutionary AVERSA™ Technology Sets New Standard for Opioid Patch Safety ORLANDO, FL / September 20, 2023 - Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a leading developer of transdermal pharmaceutical products, proudly announces the issuance of a U.S. patent for its cutting-edge AVERSA™ Technology. This groundbreaking innovation, utilizing taste aversion, marks a paradigm shift in addressing the primary routes of abuse associated with opioid-based transdermal patches. The newly granted patent, numbered U.S. patent 11,759,431, titled "Abuse and Misuse Deterrent Transdermal Systems," significantly bolsters Nutriband's intellectual property protection in the United States. It covers

Starbox Group’s StarboxAI – ViPro Module: Transforming Content Creation

Source Node:
Time Stamp: September 5, 2023 12:41 PM - Modified On: September 5, 2023 - Published By:
Source Cluster:
Republished By Plato

Kuala Lumpur, Malaysia, Sept 5th, 2023 – Starbox Group Holdings Ltd. (Nasdaq: STBX), a dynamic player in cash rebates, digital advertising, and payment solutions, with a vision of leading in artificial intelligence (“AI”) solutions throughout Southeast Asia, is making waves with the launch of its groundbreaking StarboxAI - ViPro module. This innovative module introduces a text-to-video feature set to redefine content creation. The Text-to-Video feature within the StarboxAI - ViPro module is not just an addition; it's a revelation. It empowers content creators to seamlessly transmute textual instructions or scripts

Starbox Group Holdings Ltd. Announces First Half of Fiscal Year 2023 Financial Results

Source Node:
Time Stamp: August 29, 2023 11:37 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Revenue and Net Profit Increased with Technology Driven Services Revenue Accounted for Approximately 43.8% of its Revenue KUALA LUMPUR, Malaysia, August 29, 2023 / Plato / Amplifi. Starbox Group Holdings Ltd. (Nasdaq: STBX) ("Starbox" or "the Company”), a service provider of cash rebates, digital advertising, and payment solutions with a goal of becoming a comprehensive AI solutions provider within Southeast Asia, today announced its unaudited financial results for the six months ended March 31, 2023. Mr. Lee Choon Wooi, Chairman and Chief Executive Officer of Starbox, commented, “We are excited

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Source Node:
Time Stamp: August 29, 2023 8:16 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement

Livento Group, Inc. Announces Second Quarter Results with Revenue Growth of Over 90%, Including Significant Achievements and Updates

Source Node:
Time Stamp: August 17, 2023 3:06 PM - Modified On: August 17, 2023 - Published By:
Source Cluster:
Republished By Plato

NEW YORK, NY / August 14, 2023 / NuGene International, Inc./Livento Group, Inc. (OTC Pink:NUGN), a dynamic leader specializing in the acquisition and development of companies with disruptive business models in film, content, and technology sectors, is pleased to announce revenue growth of 91.65% for the second quarter of 2023, compared to the same period in 2022. Financial Highlights: Revenue Growth:The second quarter ending June 30, 2023, saw revenues of $431,184, up from $224,986 in 2022. For the six-month period ending June 30, 2023, revenues grew from $680,202 to $922,651, a growth of

Travelzoo META Opens for Founding Members

Source Node:
Time Stamp: May 11, 2023 7:21 AM - Modified On: May 11, 2023 - Published By:
Source Cluster:
Republished By Plato

NEW YORK/PARIS/TOKYO, May 11, 2023 - (ACN Newswire) - The future of travel is here. After months of anticipation, Travelzoo META, a members-only service offering groundbreaking Metaverse travel experiences, is now accepting its first one million Founding Members. Launched by Travelzoo® (NASDAQ: TZOO), a global Internet media company, Travelzoo META will give Founding Members the opportunity to be the first to experience travel in the Metaverse. Travelzoo META's experiences are intended to allow its members to explore hard-to-reach corners of the world, like summiting Mount Everest, or travel back in time—to